XTAE
EMTC-M
Market cap4mUSD
Apr 07, Last price
18.30ILS
1D
0.00%
1Q
22.82%
Jan 2017
18,765.98%
Name
Elbit Medical Technologies Ltd
Chart & Performance
P/E
—
P/S
1,784.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-23.11%
Rev. gr., 5y
112.53%
Revenues
271k
+401.85%
Net income
-18m
L+248.15%
CFO
-590k
L+12.17%
Earnings
Apr 16, 2025
Profile
Elbit Medical Technologies Ltd, an investment holding company, engages in the research, development, production, and marketing of therapeutic medical systems in the United States, Europe, and internationally. The company is developing a magnetic resonance imaging guided focused ultrasound treatment equipment to address various oncology and gynecology indications, as well as neurological disorders and tumors. It is also involved in the study and development of medical products based on stem cells originating primarily from the umbilical cord blood that are used for bone marrow transplants in the patients of leukemia or cancer of lymph nodes, non-malignant blood diseases, and metabolic genetic disorders. The company is based in Petah Tikva, Israel. Elbit Medical Technologies Ltd is a subsidiary of Exigent Management Ltd.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 271 401.85% | 54 | |||||||
Cost of revenue | 51,742 | 35,731 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (51,471) | (35,677) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (556) | ||||||||
Tax Rate | |||||||||
NOPAT | (51,471) | (35,121) | |||||||
Net income | (17,794) 248.15% | (5,111) -67.07% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (411) | ||||||||
BB yield | 82.35% | ||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (7,405) | (23,525) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (590) | (526) | |||||||
CAPEX | |||||||||
Cash from investing activities | 2,020 | (1,958) | |||||||
Cash from financing activities | (411) | ||||||||
FCF | (51,471) | (35,121) | |||||||
| Balance | |||||||||
Cash | 1,649 | 2,253 | |||||||
Long term investments | 5,756 | 21,272 | |||||||
Excess cash | 7,391 | 23,522 | |||||||
Stockholders' equity | (75,459) | 55,096 | |||||||
Invested Capital | 82,676 | 1,489 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 90,716 | 90,738 | |||||||
Price | 0.00 -52.55% | 0.01 -68.75% | |||||||
Market cap | 237 -52.56% | 499 -68.17% | |||||||
EV | (7,168) | (23,026) | |||||||
EBITDA | (51,471) | (35,677) | |||||||
EV/EBITDA | 0.14 | 0.65 | |||||||
Interest | |||||||||
Interest/NOPBT | |||||||||